A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
The goal of this clinical research study is to compare the safety and effectiveness of the study drug SGI-110 (guadecitabine) to current standard treatment.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Cytarabine,Decitabine,Fludarabine,G-CSF,Guadecitabine,Idarubicin
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Astex Pharmaceuticals, Inc.
IRB Review and Approval Date: 06/29/2017
Recruitment Status: Open
Projected Accrual: 404
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: